前列腺癌根治术后淋巴结转移患者辅助放疗联合雄激素剥夺治疗:获益人群识别
ADT+EBRT较观察(HR 0.77,95%CI 0.64–0.94,P=0.008)和较ADT(HR 0.76,95%CI 0.63–0.93,P=0.007)均改善总生存;ADT与观察无差异(HR 1.01,95%CI 0.87–1.18,P=0.88)。无高危病理特征的患者未见显著OS获益。
要点
- 根治术后pN1患者中,ADT+EBRT较观察和ADT均改善总生存。
- ADT单药与观察相比总生存无显著差异。
- 无≥pT3b、Gleason≥9、≥3枚阳性淋巴结或切缘阳性者未见辅助治疗OS获益。
核心结论
- 根治术后淋巴结转移患者中,ADT+EBRT在多数患者中改善总生存,尤其是有不良病理特征者。
- 无高危特征的患者(占比可达31.6%)辅助治疗未带来显著OS获益,可考虑观察。
研究设计与样本
- 回顾性队列研究,使用美国国家癌症数据库2004–2013年数据。
- 排除根治术前使用放疗或ADT、临床M1疾病或随访数据不完整者。
- 主要结局为总生存,采用Kaplan-Meier曲线和多因素Cox比例风险模型。
主要发现
- 平均(中位;四分位距)随访52.3(48.0;28.5–73.5)个月。
- 接受ADT或ADT+EBRT者病理Gleason评分、T分期、切缘阳性率和淋巴结负荷更高。
- ADT+EBRT对比观察:HR 0.77,95%CI 0.64–0.94,P=0.008。
- ADT+EBRT对比ADT:HR 0.76,95%CI 0.63–0.93,P=0.007。
- ADT对比观察:HR 1.01,95%CI 0.87–1.18,P=0.88;限制辅助治疗时机后结果相似。
临床怎么用
- 根治术后pN1且伴不良病理特征者,可考虑ADT+EBRT以改善总生存。
- 无高危特征者可选择观察,避免立即ADT或放疗相关并发症。
局限性
- 回顾性数据库研究,存在选择偏倚可能。
- 辅助治疗组病理特征更差,需谨慎解读组间比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To perform a comparative analysis of three current management strategies for patients with lymph node metastases (LNM; pN1) following radical prostatectomy (RP): observation, androgen-deprivation therapy (ADT), and external beam radiation therapy (EBRT) + ADT. PATIENTS AND METHODS: Patients with LNM after RP were identified using the National Cancer Database (2004-2013). Exclusion criteria included any use of radiation therapy or ADT before RP, clinical M1 disease, or incomplete follow-up data. Patients were categorised according to postoperative management strategy. The primary outcome was overall survival (OS). Kaplan-Meier curves and adjusted multivariable Cox proportional hazards models were employed. Sub-analyses further evaluated patient risk stratification and time to receipt of adjuvant therapy. RESULTS: A total of 8 074 patients met the inclusion criteria. Postoperatively, 4 489 (55.6%) received observation, 2 065 (25.6%) ADT, and 1 520 (18.8%) ADT + EBRT. The mean (median; interquartile range) follow-up was 52.3 (48.0; 28.5-73.5) months. Patients receiving ADT or ADT + EBRT had higher pathological Gleason scores, T-stage, positive surgical margin rates, and nodal burden. Adjusted multivariable Cox models showed improved OS for ADT + EBRT vs observation (hazard ratio [HR] 0.77, 95% confidence interval [CI] 0.64-0.94; P = 0.008) and vs ADT (HR 0.76, 95% CI: 0.63-0.93; P = 0.007). There was no difference in OS for ADT vs observation (HR 1.01, 95% CI: 0.87-1.18; P = 0.88). Findings were similar when restricting adjuvant cohorts for timing of adjuvant therapy. There was no difference in OS between groups for up to 2 549 (31.6%) patients lacking any of the following adverse features: ≥pT3b disease, Gleason score ≥9, three or more positive nodes, or positive surgical margin. CONCLUSIONS: For patients with LNM after RP, the use of adjuvant ADT + EBRT improved OS in the majority of patients, especially those with adverse pathological features. Conversely, adjuvant therapy did not confer significant OS benefit in up to 30% of patients without high-risk features, who may be managed with observation and forego the morbidity associated with immediate ADT or radiation.
引用
- Gupta M, Patel HD, Schwen ZR, et al. Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit. BJU Int. 2018. PMID: 29626845. doi:10.1111/bju.14241
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。